Literature DB >> 13069256

Clinical use of hydralazine and hexamethonium in treatment of hypertension.

R R HILKER, P S RHOADS, C E BILLINGS.   

Abstract

Entities:  

Keywords:  HYPERTENSION/therapy; MUSCLE RELAXANTS/therapeutic use; SYMPATHOLYTICS/therapeutic use

Mesh：

Substances：

Year:  1953        PMID： 13069256     DOI： 10.1001/jama.1953.02940180007002

Source DB:  PubMed          Journal:  J Am Med Assoc        ISSN： 0002-9955


× No keyword cloud information.
  5 in total

1.  [Comparative clinical studies on the effect of hydrazinophthalazine and Rauwolfia alkaloid reserpin on the blood pressure].

Authors:  K KUHNS; R DJURANOVIC; C GEHRS; K KOPPEN
Journal:  Klin Wochenschr       Date:  1954-10-01

2.  Hexamethonium contributing to fatal shock in hypertensive epistaxis.

Authors:  A K HRENOFF
Journal:  Calif Med       Date:  1954-12

3.  Rap1b in smooth muscle and endothelium is required for maintenance of vascular tone and normal blood pressure.

Authors:  Sribalaji Lakshmikanthan; Bartosz J Zieba; Zhi-Dong Ge; Ko Momotani; Xiaodong Zheng; Hayley Lund; Mykhaylo V Artamonov; Jason E Maas; Aniko Szabo; David X Zhang; John A Auchampach; David L Mattson; Avril V Somlyo; Magdalena Chrzanowska-Wodnicka
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-05-01       Impact factor: 8.311

4.  A comparison of the effects of hexamethonium alone and in combination with 1-hydrazinophthalazine (apresoline) in the treatment of hypertension.

Authors:  E S ORGAIN; C L RAST; H A SIEBER
Journal:  Trans Am Clin Climatol Assoc       Date:  1953

5.  Covalent adduct formation between the antihypertensive drug hydralazine and abasic sites in double- and single-stranded DNA.

Authors:  Douglas Melton; Calvin D Lewis; Nathan E Price; Kent S Gates
Journal:  Chem Res Toxicol       Date:  2014-11-18       Impact factor: 3.739
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.